Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Alzheimer Disease and Associated Disorders

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002093-199700112-00004PMID 9236949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimer's Disease Clinical Trials: Overview and General Results

  1997cited by this paper
• Clinical Evaluation of Global Change in Alzheimer's Disease: Identifying Consensus

  1996cited by this paper
• Overview of clinical trials of hydergine in dementia.

  1994cited by this paper
• A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

  1994cited by this paper
• The Clinician Interview‐ Based Impression (CIBI)

  1994cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1993cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research.

  1992cited by this paper
• Functional assessment staging (FAST).

  1988cited by this paper
• Clinical Dementia Rating (CDR).

  1988cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper
• Practicable and Valid Approach to Evaluate the Efficacy of Nootropic Drugs by Means of Rating Scales

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• The Global Deterioration Scale for assessment of primary degenerative dementia.

  1982cited by this paper
• A New Scale for Clinical Assessment in Geriatric Populations: Sandoz Clinical Assessment – Geriatric (SCAG) *

  1974cited by this paper

• Ginkgo biloba for cognitive impairment and dementia.

  2026cites this paper
• Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial.

  2025cites this paper
• Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB)

  2025cites this paper
• Testing the Clinical Dementia Rating Sum of Boxes as an Outcome for Dementia with Lewy Bodies Clinical Trials

  2025cites this paper
• The double-edged roles of testosterone in cognitive function and behavioral/psychological symptoms of patients with dementia.

  2025cites this paper
• Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects.

  2025cites this paper
• Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia – a meta-analysis of patient subgroups in randomised controlled trials

  2025cites this paper
• Efficacy and safety of transcutaneous auricular vagus nerve stimulation plus pregabalin for radiotherapy-related neuropathic pain in patients with head and neck cancer (RELAX): a phase 2 randomised trial

  2025cites this paper
• Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons With Dementia: A Randomized Trial.

  2025cites this paper
• Non-pharmacological interventions to reduce neuropsychiatric symptoms in hospitalised patients for behavioural crises with cognitive impairment: A systematic review.

  2025cites this paper
• Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial

  2025cites this paper
• A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.

  2025cites this paper
• Musical Engagement of brain LObes in Alzheimer's Disease patients study (MELODY): A randomized controlled trial.

  2025cites this paper
• Electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD): A modified study protocol

  2024cites this paper
• Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.

  2024cites this paper
• Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures

  2024cites this paper
• A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease

  2024cites this paper
• Multifaceted Interventions Inclusive of Medication Optimization for Frailty in Aged Care: A Systematic Review.

  2024cites this paper
• Feasibility and Preliminary Efficacy of American Elderberry Juice for Improving Cognition and Inflammation in Patients with Mild Cognitive Impairment

  2024cites this paper
• Evaluating the treatment outcomes of repetitive transcranial magnetic stimulation in patients with moderate-to-severe Alzheimer’s disease

  2023cites this paper
• Cognitive aspects of Alzheimer's

  2023cites this paper
• Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorder

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial.

  2023cites this paper
• Efficacy of transcutaneous auricular vagus nerve stimulation on radiotherapy-related neuropathic pain in patients with head and neck cancers (RELAX): protocol for a multicentre, randomised, double-blind, sham-controlled trial

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Outcome measures for Alzheimer’s disease: A global inter-societal Delphi consensus

  2023cites this paper
• Cognitive aspects of Alzheimer's

  2023cites this paper
• Cognitive aspects of Alzheimer's

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Cognitive aspects of Alzheimer'

  2023cites this paper
• Adjunctive transcranial direct current stimulation (tDCS) plus sodium benzoate for the treatment of early-phase Alzheimer's disease: A randomized, double-blind, placebo-controlled trial.

  2023cites this paper
• Remotely supervised at-home delivery of taVNS for autism spectrum disorder: feasibility and initial efficacy

  2023influential citation
• Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

  2023cites this paper
• The Rationale and Design of Behavioral Interventions for Management of Agitation in Dementia in a Multi-Site Clinical Trial

  2022cites this paper
• Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

  2022cites this paper
• Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

  2022cites this paper
• Clinical Data Interchange Standards in Clinical Trials on Alzheimer’s Disease

  2022cites this paper
• WBI Studies Repository WBI Studies Clinical trials and late-stage drug development in Alzheimer’s Clinical trials and late-stage drug development in Alzheimer’s disease: An appraisal from 1984 to 2014 disease: An appraisal from 1984 to 2014

  2022cites this paper
• Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

  2022cites this paper
• Design of a Multi-Epitopes Based Chimeric Vaccine against Enterobacter cloacae Using Pan-Genome and Reverse Vaccinology Approaches

  2022cites this paper
• Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease

  2022cites this paper
• Simulated Electroconvulsive Therapy

  2022influential citation
• Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease

  2022influential citation
• Proposed research criteria for prodromal behavioural variant frontotemporal dementia

  2022cites this paper
• A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

  2022cites this paper
• The Clinician's Interview‐Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response

  2021cites this paper
• The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study

  2021cites this paper
• A systematic review and meta-analysis of the clinical effects of Souvenaid in patients with Alzheimer's disease.

  2021cites this paper
• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

  2021cites this paper
• Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies.

  2021cites this paper
• Past, Present, and Future of Non-invasive Brain Stimulation Approaches to Treat Cognitive Impairment in Neurodegenerative Diseases: Time for a Comprehensive Critical Review

  2021cites this paper
• Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer’s Disease: A Multicenter, Prospective Cohort Study

  2021cites this paper
• Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer’s Disease: A Phase II Double-Blind Placebo-Controlled Trial

  2021cites this paper
• Clinical Trials for Cognitive Impairment and Dementia in Parkinson’s Disease

  2021cites this paper
• Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.

  2021cites this paper
• A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer’s Disease

  2021cites this paper
• Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial

  2021cites this paper
• Gamma‐induction in frontotemporal dementia (GIFTeD) randomized placebo‐controlled trial: Rationale, noninvasive brain stimulation protocol, and study design

  2021cites this paper
• The consequences of COVID-19 lockdown for formal and informal resource utilization among home-dwelling people with dementia: results from the prospective PAN.DEM study

  2021cites this paper
• Anti-dementia Medication

  2021cites this paper
• An Exploratory Investigation of Goal Management Training in Adults With ADHD: Improvements in Inhibition and Everyday Functioning

  2021cites this paper
• Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.

  2021cites this paper
• Vortioxetine improves cognition in mild cognitive impairment

  2021cites this paper
• Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria

  2021cites this paper
• Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus cholinesterase inhibition to reduce neurologic decline in Alzheimer's.

  2021cites this paper
• An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)

  2021cites this paper
• Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)

  2021cites this paper
• Parkinson disease-associated cognitive impairment

  2021cites this paper
• Enhancing sleep quality for nursing home residents with dementia: a pragmatic randomized controlled trial of an evidence-based frontline huddling program

  2020cites this paper
• The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology

  2020cites this paper
• Souvenaid for Alzheimer's disease.

  2020cites this paper
• Longitudinal Course of Agitation and Aggression in Patients with Alzheimer’s Disease in a Cohort study: Methods, Baseline and Longitudinal Results of the A3C Study

  2020cites this paper
• Nucleus Basalis of Meynert Stimulation for Lewy Body Dementia

  2020cites this paper
• Memantine and Alzheimer's disease

  2020cites this paper
• Dementia and usage of N-methyl-d-aspartate receptor antagonists

  2020cites this paper
• Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

  2020cites this paper
• Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review

  2020cites this paper
• for Cognitive Impairment and Dementia in Parkinson’s

  2020cites this paper
• Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest).

  2020cites this paper
• Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia

  2020cites this paper
• Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

  2020cites this paper
• One Year of CPAP Adherence Improves Cognition in Older Adults with Mild Apnea and Mild Cognitive Impairment: A Secondary Analysis of Memories 1

  2020influential citation
• One Year of CPAP Adherence Improves Cognition in Older Adults with Mild Apnea and Mild Cognitive Impairment.

  2020cites this paper
• Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial

  2020cites this paper
• A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer’s Disease

  2020cites this paper
• Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial

  2020influential citation
• DL-3-n-butylphthalide Delays Cognitive Decline in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil: A Multicenter, Prospective Cohort Study

  2020cites this paper
• The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS).

  2019cites this paper
• Practice of Epidemiology Diagnosing Covariate Balance Across Levels of Right-Censoring Before and After Application of Inverse-Probability-of-CensoringWeights

  2019cites this paper
• Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial.

  2019cites this paper
• Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis

  2019cites this paper
• Escitalopram for agitation in Alzheimer's disease (S‐CitAD): Methods and design of an investigator‐initiated, randomized, controlled, multicenter clinical trial

  2019cites this paper
• Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

  2019cites this paper
• Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease

  2019cites this paper
• Diagnosing Covariate Balance Across Levels of Right-Censoring, Before and After Applying Inverse Probability of Censoring Weights.

  2019cites this paper